Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Participants With Worsening Heart Failure

NCT03292653 | Terminated Phase 2 Results DMC FDA Drug

• 3 other identifiers: PDY150792017-002774-39U1111-1190-7962
• Study Type: interventional
• Target: 32
• Locations: 3 countries
• Sites: 6

Brief Summary

Primary Objectives:

• Assess the safety and tolerability of sotagliflozin in hemodynamically stable participants with worsening of heart failure, compared to placebo.
• Estimate the effects of sotagliflozin on plasma volume changes in hemodynamically stable participants with worsening of heart failure, compared to placebo. Secondary Objectives:
• Explore the effect of sotagliflozin on erythropoiesis, as assessed by changes in plasma erythropoietin levels, in hemodynamically stable participants with worsening of heart failure, compared to placebo.
• Explore the effect of sotagliflozin on changes in plasma N-terminal prohormone of brain natriuretic peptide (NT-proBNP) levels, in hemodynamically stable participants with worsening of heart failure, compared to placebo.

Conditions

Cardiac Failure Aggravated

Outcome Measures

Primary Outcomes (6)

• Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), AEs of Special Interest (AESIs), AEs Leading to Discontinuation From the Investigational Medicinal Product (IMP) and Deaths

  AE: is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. SAEs: an event that results in death; an event that, in the view of the investigator, places the participants at immediate risk of death (a life-threatening event); an outcome that results in a congenital anomaly/birth defect diagnosed in a child of a participant; an event that requires or prolongs inpatient hospitalization; an event that results in persistent or significant disability/incapacity. AESI: is an adverse event (serious or nonserious) of scientific and medical concern, specific to the IMP or program, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor may be appropriate.

  Baseline up to Day 14

• Change From Baseline in Hemoconcentration as Assessed by Changes in Albumin to Day 14

  Baseline to Day 14

• Change From Baseline in Hemoconcentration as Assessed by Changes in Hematocrit to Day 14

  Baseline to Day 14

• Change From Baseline in Hemoconcentration as Assessed by Changes in Hemoglobin to Day 14

  Baseline to Day 14

• Change From Baseline in Hemoconcentration as Assessed by Changes in Total Protein to Day 14

  Baseline to Day 14

• Changes From Baseline in Plasma Volume to Day 14

  Change in plasma volume in milliliters (mL) was assessed by the indicator dilution method using 131I-labelled human albumin.

  Baseline to 14 Days

Secondary Outcomes (2)

• Change From Baseline in Erythropoietin to Day 14

  Baseline to Day 14

• Change From Baseline in N-terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP) to Day 14

  Baseline to Day 14

Study Arms (3)

Placebo

PLACEBO COMPARATOR

Participants were randomized to matching placebo to sotagliflozin administered as two tablets, once daily, before the first meal of the day in the double-blind treatment period for up to 14 days.

Drug: Placebo

Sotagliflozin 200 mg

EXPERIMENTAL

Participants were randomized to Sotagliflozin 200 mg administered as 1 sotagliflozin tablet and 1 matching placebo tablet, once daily, before the first meal of the day in the double-blind treatment period for up to 14 days.

Drug: Sotagliflozin; Drug: Placebo

Sotagliflozin 400 mg

EXPERIMENTAL

Participants were randomized to Sotagliflozin 400 mg administered as two 200 mg sotagliflozin tablets, once daily, before the first meal of the day in the double-blind treatment period for up to 14 days.

Drug: Sotagliflozin

Interventions

Sotagliflozin DRUG

Pharmaceutical form: Tablet; Route of administration: Oral

Also known as: SAR439954

Sotagliflozin 200 mg; Sotagliflozin 400 mg

Placebo DRUG

Pharmaceutical form: Tablet; Route of administration: Oral

Placebo; Sotagliflozin 200 mg

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Written informed consent.
• years of age or older.
• Participants admitted to the hospital or had urgent visit to emergency department or heart failure unit/clinic or infusion center for Congestive Heart Failure (CHF), defined by:
• Presence of ≥2 of the following clinical signs and symptoms of congestion: jugular venous distension, pitting edema in lower extremities greater than trace, dyspnea, rales heard on auscultation, radiographic pulmonary congestion, weight gain above historical dry weight of at least 5 pounds (lbs) (2.27 Kilograms (kg)).
• Requiring treatment with intravenous (IV) diuretics.
• Estimated glomerular filtration rate (eGFR) ≥30 milliliter per minute (mL/min)/1.73 square meter (m\^2) at the screening or randomization visit by the 4 variable Modification of Diet in Renal Disease (MDRD) equation.
• Female participants must use a double contraception method during the study including a highly effective method of birth control, except if she has undergone sterilization at least 3 months earlier or is postmenopausal.
• Male participants, unless vasectomized and confirmed sterile by sperm analysis, must use condoms during the study and refrain from donating sperm up to 90 days after the day of last dose. If the participant has a female partner of childbearing potential, the participant must wear a condom and female partner must use at least 1 highly effective method of birth control during the study treatment period and the Follow-up period.
• Transitioning from IV to oral diuretics, and oral diuretic treatment has been prescribed or administered.
• Hemodynamically stable, defined as systolic blood pressure (SBP) \>100 millimeters of mercury (mmHg) with no requirement for IV inotropes or IV vasodilators.

You may not qualify if:

• History of Type 1 diabetes mellitus.
• Appears unlikely or unable to participate in the required study procedures, as assessed by the study Investigator, study coordinator, or designee (ex: clinically-significant psychiatric, addictive, or neurological disease), or sectioned due to an official or court order.
• Current admission or visit for Worsening Heart Failure (HF) that is clearly and primarily triggered by causes such as tachyarrhythmia (example: sustained ventricular tachycardia, or atrial fibrillation/flutter with sustained ventricular response \> 130 beats per minute), acute coronary syndrome, pulmonary embolism, cerebrovascular accident, heart valve disorders (such as severe aortic stenosis), as determined by the Investigator.
• Participants who recently had or scheduled to have cardiac interventions may be eligible if:
• Stable 48 hours post procedure.
• Have diuretic treatment planned for the duration of treatment in this study.
• Current use of or recent suspension of digoxin therapy with high levels of digoxin (level should be obtained and must be \<1.2 nanograms per milliliter (ng/mL) at screening.
• History of heart or kidney transplant.
• Diagnosis of hypertrophic obstructive cardiomyopathy.
• End-stage HF defined as requiring left ventricular assist device insertion, intra-aortic balloon placement (IABP), or any type of mechanical support during the study period.
• Pregnancy (demonstrated by serum pregnancy test at screening), breast-feeding, or inability or refusal to undergo pregnancy testing.
• Use of any investigational drug(s) or prohibited therapy or sodium-glucose co-transporter 2 (SGLT2) 5 half-lives prior to screening.
• Participants with moderate or severe respiratory, hepatic, neurological, psychiatric, active malignant tumor or other major systemic disease (including any diseases with evidence of malabsorption), making implementation of the protocol and/or the interpretation of the study results difficult.
• Known allergies, hypersensitivity, or intolerance to sotagliflozin or any inactive component of sotagliflozin or placebo (ie, microcrystalline cellulose, croscarmellose sodium \[disintegrant\], talc, silicon dioxide, and magnesium stearate \[non-bovine\]), unless the reaction is deemed irrelevant to the study by the PI.
• Laboratory findings at the Screening Visit:

Sponsors & Collaborators

• Lexicon Pharmaceuticals: lead
• Sanofi: collaborator

Study Sites (6)

Investigational Site Number 8400005

La Jolla, California, 92037, United States

Location

Investigational Site Number 8400001

New Haven, Connecticut, 06510, United States

Location

Investigational Site Number 8400007

Rochester, Minnesota, 55905, United States

Location

Investigational Site Number 8400002

Cleveland, Ohio, 44195, United States

Location

Investigational Site Number 1240001

Toronto, M5G 2N2, Canada

Location

Investigational Site Number 5280001

Groningen, 9713 GZ, Netherlands

Location

MeSH Terms

Interventions

(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol

Results Point of Contact

• Title: Medical Affairs
• Organization: Lexicon Pharmaceuticals, Inc.

medical-information@lexpharma.com

(510) 338-6064

Study Officials

• Suman Wason, MD

  Lexicon Pharmaceuticals, Inc.

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 20, 2017
• First Posted: September 25, 2017
• Study Start: December 4, 2017
• Primary Completion: August 17, 2019
• Study Completion: August 17, 2019
• Last Updated: May 11, 2021
• Results First Posted: May 11, 2021

Record last verified: 2021-04

Data Sharing

• IPD Sharing: Will not share

Locations

CA (1); NL (1); US (4)